Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

INNV vs DBVT vs ALKS vs ALHC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
INNV
InnovAge Holding Corp.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$1.10B
5Y Perf.-68.7%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-62.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+89.5%
ALHC
Alignment Healthcare, Inc.

Medical - Healthcare Plans

HealthcareNASDAQ • US
Market Cap$3.73B
5Y Perf.-16.8%

INNV vs DBVT vs ALKS vs ALHC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
INNV logoINNV
DBVT logoDBVT
ALKS logoALKS
ALHC logoALHC
IndustryMedical - Care FacilitiesBiotechnologyBiotechnologyMedical - Healthcare Plans
Market Cap$1.10B$1712.35T$5.90B$3.73B
Revenue (TTM)$946M$0.00$1.56B$4.26B
Net Income (TTM)$-22M$-168M$153M$20M
Gross Margin14.8%65.4%9.0%
Operating Margin1.5%12.3%0.8%
Forward P/E32.0x24.8x140.9x
Total Debt$101M$22M$70M$338M
Cash & Equiv.$64M$194M$1.12B$578M

INNV vs DBVT vs ALKS vs ALHCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

INNV
DBVT
ALKS
ALHC
StockMar 21May 26Return
InnovAge Holding Co… (INNV)10031.3-68.7%
DBV Technologies S.… (DBVT)10037.5-62.5%
Alkermes plc (ALKS)100189.5+89.5%
Alignment Healthcar… (ALHC)10083.2-16.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: INNV vs DBVT vs ALKS vs ALHC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Alignment Healthcare, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. INNV also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
INNV
InnovAge Holding Corp.
The Income Pick

INNV is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.66
  • +147.9% vs ALKS's +16.5%
Best for: income & stability
DBVT
DBV Technologies S.A.
The Secondary Option

DBVT lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ALKS
Alkermes plc
The Defensive Pick

ALKS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Lower P/E (24.8x vs 140.9x)
  • 9.8% margin vs INNV's -2.3%
  • 5.4% ROA vs DBVT's -89.0%
Best for: sleep-well-at-night
ALHC
Alignment Healthcare, Inc.
The Insurance Pick

ALHC is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
  • 5.4% 10Y total return vs ALKS's -11.0%
  • Beta 0.75, current ratio 1.74x
  • 46.1% revenue growth vs DBVT's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthALHC logoALHC46.1% revenue growth vs DBVT's -100.0%
ValueALKS logoALKSLower P/E (24.8x vs 140.9x)
Quality / MarginsALKS logoALKS9.8% margin vs INNV's -2.3%
Stability / SafetyALHC logoALHCBeta 0.75 vs INNV's 1.66
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)INNV logoINNV+147.9% vs ALKS's +16.5%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

INNV vs DBVT vs ALKS vs ALHC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

INNVInnovAge Holding Corp.
FY 2025
Other Operating Segment
100.0%$990,000
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
ALHCAlignment Healthcare, Inc.
FY 2023
Health Care, Premium
92.6%$1.7B
Health Care Capitation
7.4%$133M

INNV vs DBVT vs ALKS vs ALHC — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

ALHC and DBVT operate at a comparable scale, with $4.3B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to INNV's -2.3%. On growth, ALHC holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricINNV logoINNVInnovAge Holding …DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcALHC logoALHCAlignment Healthc…
RevenueTrailing 12 months$946M$0$1.6B$4.3B
EBITDAEarnings before interest/tax$4M-$112M$212M$66M
Net IncomeAfter-tax profit-$22M-$168M$153M$20M
Free Cash FlowCash after capex$39M-$151M$392M$237M
Gross MarginGross profit ÷ Revenue+14.8%+65.4%+9.0%
Operating MarginEBIT ÷ Revenue+1.5%+12.3%+0.8%
Net MarginNet income ÷ Revenue-2.3%+9.8%+0.5%
FCF MarginFCF ÷ Revenue+4.1%+25.1%+5.6%
Rev. Growth (YoY)Latest quarter vs prior year+15.5%+28.2%+33.3%
EPS Growth (YoY)Latest quarter vs prior year-161.3%+91.5%-4.1%+2.1%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ALKS and ALHC each lead in 2 of 6 comparable metrics.

On an enterprise value basis, ALKS's 17.3x EV/EBITDA is more attractive than ALHC's 77.1x.

MetricINNV logoINNVInnovAge Holding …DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcALHC logoALHCAlignment Healthc…
Market CapShares × price$1.1B$1712.35T$5.9B$3.7B
Enterprise ValueMkt cap + debt − cash$1.1B$1712.35T$4.9B$3.5B
Trailing P/EPrice ÷ TTM EPS-36.73x-0.76x24.76x-4932.43x
Forward P/EPrice ÷ next-FY EPS est.32.03x140.93x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.25x77.12x
Price / SalesMarket cap ÷ Revenue1.28x4.00x0.94x
Price / BookPrice ÷ Book value/share4.16x0.66x3.28x20.16x
Price / FCFMarket cap ÷ FCF41.22x12.28x32.95x
Evenly matched — ALKS and ALHC each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 7 of 9 comparable metrics.

ALHC delivers a 11.5% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricINNV logoINNVInnovAge Holding …DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcALHC logoALHCAlignment Healthc…
ROE (TTM)Return on equity-8.2%-130.2%+8.8%+11.5%
ROA (TTM)Return on assets-4.1%-89.0%+5.4%+1.8%
ROICReturn on invested capital-6.8%+18.9%
ROCEReturn on capital employed-7.1%-145.7%+14.2%+2.9%
Piotroski ScoreFundamental quality 0–96476
Debt / EquityFinancial leverage0.38x0.13x0.04x1.89x
Net DebtTotal debt minus cash$37M-$172M-$1.0B-$240M
Cash & Equiv.Liquid assets$64M$194M$1.1B$578M
Total DebtShort + long-term debt$101M$22M$70M$338M
Interest CoverageEBIT ÷ Interest expense5.96x-189.82x32.30x1.27x
ALKS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ALHC leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, INNV leads with a +147.9% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors ALHC at 36.2% vs ALKS's 4.6% — a key indicator of consistent wealth creation.

MetricINNV logoINNVInnovAge Holding …DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcALHC logoALHCAlignment Healthc…
YTD ReturnYear-to-date+55.7%+4.9%+25.3%-9.7%
1-Year ReturnPast 12 months+147.9%+110.4%+16.5%+17.6%
3-Year ReturnCumulative with dividends+24.5%+19.7%+14.5%+152.4%
5-Year ReturnCumulative with dividends-68.5%-69.1%+60.9%-22.7%
10-Year ReturnCumulative with dividends-66.6%-87.0%-11.0%+5.4%
CAGR (3Y)Annualised 3-year return+7.6%+6.2%+4.6%+36.2%
ALHC leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and ALHC each lead in 1 of 2 comparable metrics.

ALHC is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than INNV's 1.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs INNV's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricINNV logoINNVInnovAge Holding …DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcALHC logoALHCAlignment Healthc…
Beta (5Y)Sensitivity to S&P 5001.66x1.26x1.06x0.75x
52-Week HighHighest price in past year$10.68$26.18$36.60$23.87
52-Week LowLowest price in past year$2.85$7.53$25.17$11.63
% of 52W HighCurrent price vs 52-week peak+75.7%+76.3%+96.7%+76.5%
RSI (14)Momentum oscillator 0–10050.248.160.237.3
Avg Volume (50D)Average daily shares traded291K252K2.3M3.6M
Evenly matched — ALKS and ALHC each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: INNV as "Hold", DBVT as "Buy", ALKS as "Buy", ALHC as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -15.8% for INNV (target: $7).

MetricINNV logoINNVInnovAge Holding …DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcALHC logoALHCAlignment Healthc…
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuy
Price TargetConsensus 12-month target$6.80$46.33$44.00$24.83
# AnalystsCovering analysts8152816
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises000
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.7%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ALHC leads in 1 (Total Returns). 2 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

INNV vs DBVT vs ALKS vs ALHC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is INNV or DBVT or ALKS or ALHC a better buy right now?

For growth investors, Alignment Healthcare, Inc.

(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — INNV or DBVT or ALKS or ALHC?

On forward P/E, InnovAge Holding Corp.

is actually cheaper at 32. 0x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — INNV or DBVT or ALKS or ALHC?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ALHC returned +5. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — INNV or DBVT or ALKS or ALHC?

By beta (market sensitivity over 5 years), Alignment Healthcare, Inc.

(ALHC) is the lower-risk stock at 0. 75β versus InnovAge Holding Corp. 's 1. 66β — meaning INNV is approximately 122% more volatile than ALHC relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — INNV or DBVT or ALKS or ALHC?

By revenue growth (latest reported year), Alignment Healthcare, Inc.

(ALHC) is pulling ahead at 46. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALHC leads at 40. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — INNV or DBVT or ALKS or ALHC?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -3. 6% for InnovAge Holding Corp. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -3. 5% for INNV. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is INNV or DBVT or ALKS or ALHC more undervalued right now?

On forward earnings alone, InnovAge Holding Corp.

(INNV) trades at 32. 0x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 108. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — INNV or DBVT or ALKS or ALHC?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is INNV or DBVT or ALKS or ALHC better for a retirement portfolio?

For long-horizon retirement investors, Alignment Healthcare, Inc.

(ALHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). InnovAge Holding Corp. (INNV) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALHC: +5. 4%, INNV: -66. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between INNV and DBVT and ALKS and ALHC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INNV is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ALHC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

INNV

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

ALHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 16%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.